Free Trial

Mangoceuticals (MGRX) Competitors

Mangoceuticals logo
$1.64 +0.16 (+10.81%)
Closing price 05/22/2025 04:00 PM Eastern
Extended Trading
$1.60 -0.03 (-2.13%)
As of 04:51 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MGRX vs. MRAI, ENZ, BRTX, OTRK, SSY, BGLC, ACON, DHAC, ATIP, and VSEE

Should you be buying Mangoceuticals stock or one of its competitors? The main competitors of Mangoceuticals include Marpai (MRAI), Enzo Biochem (ENZ), BioRestorative Therapies (BRTX), Ontrak (OTRK), SunLink Health Systems (SSY), BioNexus Gene Lab (BGLC), Aclarion (ACON), Digital Health Acquisition (DHAC), ATI Physical Therapy (ATIP), and Vsee Health (VSEE). These companies are all part of the "healthcare" industry.

Mangoceuticals vs.

Mangoceuticals (NASDAQ:MGRX) and Marpai (NASDAQ:MRAI) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation.

Marpai has a net margin of -85.70% compared to Mangoceuticals' net margin of -1,237.00%. Marpai's return on equity of 0.00% beat Mangoceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Mangoceuticals-1,237.00% -138.00% -118.88%
Marpai -85.70%N/A -100.23%

56.7% of Mangoceuticals shares are held by institutional investors. Comparatively, 49.8% of Marpai shares are held by institutional investors. 16.0% of Mangoceuticals shares are held by insiders. Comparatively, 61.3% of Marpai shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Mangoceuticals has higher earnings, but lower revenue than Marpai. Marpai is trading at a lower price-to-earnings ratio than Mangoceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mangoceuticals$615.87K13.76-$9.21M-$4.64-0.35
Marpai$34.87M0.57-$28.75M-$1.82-0.73

In the previous week, Mangoceuticals and Mangoceuticals both had 1 articles in the media. Marpai's average media sentiment score of 0.68 beat Mangoceuticals' score of -0.95 indicating that Marpai is being referred to more favorably in the news media.

Company Overall Sentiment
Mangoceuticals Negative
Marpai Positive

Mangoceuticals has a beta of 2.45, indicating that its share price is 145% more volatile than the S&P 500. Comparatively, Marpai has a beta of 4.74, indicating that its share price is 374% more volatile than the S&P 500.

Marpai received 2 more outperform votes than Mangoceuticals when rated by MarketBeat users.

CompanyUnderperformOutperform
MangoceuticalsN/AN/A
MarpaiOutperform Votes
2
66.67%
Underperform Votes
1
33.33%

Summary

Marpai beats Mangoceuticals on 9 of the 13 factors compared between the two stocks.

Get Mangoceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for MGRX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MGRX vs. The Competition

MetricMangoceuticalshealth & allied services, not elsewhere classified IndustryMedical SectorNASDAQ Exchange
Market Cap$8.48M$2.03B$5.33B$8.39B
Dividend YieldN/A6.96%5.21%4.11%
P/E Ratio-0.2815.8626.7919.70
Price / Sales13.763.54393.69121.79
Price / CashN/A9.3238.2534.62
Price / Book3.043.926.774.50
Net Income-$9.21M$87.49M$3.23B$248.22M
7 Day Performance11.56%-4.19%0.42%-0.80%
1 Month Performance-19.61%-6.42%9.06%11.52%
1 Year Performance-98.60%-28.11%18.55%8.99%

Mangoceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MGRX
Mangoceuticals
0.1864 of 5 stars
$1.64
+10.8%
N/A-98.4%$8.48M$615,873.00-0.283Positive News
Gap Down
MRAI
Marpai
N/A$1.16
-3.9%
N/A-33.4%$17.32M$34.87M-0.44150Gap Down
ENZ
Enzo Biochem
N/A$0.33
-14.8%
N/A-69.3%$17.03M$29.09M0.00520Gap Down
High Trading Volume
BRTX
BioRestorative Therapies
3.3303 of 5 stars
$1.56
-1.9%
$18.00
+1,057.6%
+19.0%$11.67M$401,000.00-1.027
OTRK
Ontrak
2.5034 of 5 stars
$1.56
-1.6%
$45.00
+2,793.9%
-60.9%$6.56M$10.85M-0.15250Positive News
Earnings Report
SSY
SunLink Health Systems
N/A$0.86
-0.1%
N/A+41.8%$6.05M$31.23M6.141,376Analyst Forecast
Gap Down
BGLC
BioNexus Gene Lab
0.2628 of 5 stars
$2.72
+1.1%
N/A-48.2%$4.89M$9.51M0.0030Positive News
ACON
Aclarion
1.4589 of 5 stars
$7.12
-0.7%
$11,758.50
+165,047.5%
-99.8%$4.14M$45,724.000.007Gap Down
DHAC
Digital Health Acquisition
N/A$1.11
+1.5%
N/A-92.1%$4MN/A0.002,021Gap Down
ATIP
ATI Physical Therapy
N/A$0.90
flat
N/A-81.3%$3.97M$741.86M-0.055,600
VSEE
Vsee Health
1.1625 of 5 stars
$1.10
+1.3%
$5.00
+356.6%
N/A$3.95M$6.38M0.00N/AGap Down

Related Companies and Tools


This page (NASDAQ:MGRX) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners